news
Animal study flags withdrawal risk from CBN sleep supplements
A new pre-clinical trial shows cannabinol (CBN), the cannabinoid marketed widely for insomnia, produces classic physical withdrawal signs after daily dosing. Consumers taking 5 to 10 milligrams nightly treat it like herbal tea, but the compound binds CB1 receptors directly. The findings suggest habitual users face rebound insomnia and autonomic agitation when they stop.
A new pre-clinical trial shows cannabinol (CBN), the cannabinoid marketed widely for insomnia, produces classic physical withdrawal signs after daily dosing. Consumers taking 5 to 10 milligrams nightly treat it like herbal tea, but the compound binds CB1 receptors directly. The findings suggest habitual users face rebound insomnia and autonomic agitation when they stop.
The architecture take
I used to recommend CBN gummies to anyone waking up at 3 a.m. with a racing heart. That was a mistake. The supplement aisle pitched cannabinol as CBD’s drowsy cousin: gentle, non-psychoactive, and entirely free of baggage. But CBN is an oxidized breakdown product of THC, and it binds central CB1 receptors in the brain. When researchers dosed animals daily and abruptly halted supply, the subjects showed textbook cannabinoid withdrawal (twitching, autonomic spikes, and agitated waking). That matters because daily exposure prompts your nervous system to downregulate its own endocannabinoid tone. Once you pull the bottle away, sleep pressure vanishes and rebound insomnia flares up. I stopped keeping CBN on my nightstand after watching my own latency spike without it. If a gummy is the only thing dropping your core temperature, you haven't fixed your hyperarousal. I would rather endure one rough Tuesday than rewire my baseline receptors for a chewable.